News|Articles|November 17, 2026

FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • FDA accelerated approval covers post-alectinib disease or later-line settings after multiple ALK TKIs plus platinum chemotherapy for unresectable locally advanced/metastatic ALK-positive NSCLC.
  • ALK rearrangements occurred in 2.6% of advanced NSCLC overall, rising to 9.3% in nonsmokers with nonsquamous histology and 21.6% in patients aged 18–39 years.
SHOW MORE

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

The FDA granted accelerated approval to neladalkib (Nelkarmi; Nuvalent), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC).1 The indication covers patients who previously received 1 ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or 2 or more prior ALK TKIs and platinum-based chemotherapy, in the unresectable locally advanced or metastatic setting.

ALK Rearrangements Are Uncommon in Advanced NSCLC

ALK rearrangements are found in a small share of advanced NSCLC. In a real-world analysis of 19,895 US patients with advanced disease and documented ALK testing results, overall prevalence was 2.6%, and it was highest, at 9.3%, among nonsmokers with nonsquamous histology.2 Prevalence was also higher among patients aged 18 to 39 years (21.6%) than among those aged 55 years or older (2.2%).

Nuvalent describes neladalkib as a brain-penetrant, ALK-selective inhibitor created with the aim of overcoming limitations of currently available ALK inhibitors.3 The FDA granted the application priority review, and neladalkib received breakthrough therapy and orphan drug designations.1

ALKOVE-1 Is a Single-Arm, Multicohort Trial

The approval is based on ALKOVE-1 (NCT05384626), a multicenter, single-arm, open-label, multicohort trial.1 The registry lists ALKOVE-1 as a nonrandomized phase 1/2 study sponsored by Nuvalent, with a study start in June 2022, an estimated enrollment of 840 patients, and 74 locations. The study is still recruiting.4 The phase 2 primary end point is overall response rate (ORR), assessed by blinded independent central review.

The FDA evaluated efficacy in 67 patients who had received 1 prior ALK TKI consisting of alectinib in the metastatic setting and 155 patients who had received 2 or more prior ALK TKIs and platinum-based chemotherapy.1 The agency described the groups by prior therapy rather than by the cohort labels used on the registry. The registry lists 6 phase 2 cohorts defined by factors such as the number of prior ALK TKIs, prior lorlatinib exposure, and TKI-naive status.

A separate neladalkib study, the phase 3 ALKAZAR trial (NCT06765109), is randomizing patients with treatment-naive ALK-positive NSCLC to neladalkib or alectinib and was not cited in the FDA announcement.5 Neither registry record has posted results, so the efficacy figures in this article come from the FDA announcement.

Responses Seen After Alectinib and After Multiple ALK TKIs

The major efficacy outcome measures were confirmed using ORR and duration of response (DOR) by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1.1 Among the 67 patients previously treated with alectinib, ORR was 49% (95% CI, 37%-62%). Of those who responded, 76% had a DOR of at least 6 months and 52% had a DOR of at least 12 months.

Among the 155 patients who received 2 or more ALK TKIs and platinum-based chemotherapy, ORR was 32% (95% CI, 24%-40%). In this group, 69% of responders had a DOR of at least 6 months and 51% had a DOR of at least 12 months.

The recommended dose is 150 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. The prescribing information includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. The most common adverse reactions, occurring in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.

The FDA announcement did not report intracranial response, progression-free survival, or overall survival, and it did not name a companion diagnostic. Because ALKOVE-1 is single-arm, the response rates cannot be compared directly with those of other ALK inhibitors. For clinicians and payers, the approval gives patients previously treated with alectinib, or with multiple ALK TKIs and chemotherapy, a once-daily oral targeted option.

References

  1. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. FDA. November 17, 2026. Accessed November 17, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk
  2. Allen TC, Xiao Y, Yang B, et al. Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data. Oncotarget. 2021;12(23):2308-2315. doi:10.18632/oncotarget.28114
  3. Nuvalent announces submission of new drug application to FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC. News release. Nuvalent, Inc. April 7, 2026. Accessed November 17, 2026. https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC
  4. A study of neladalkib (NVL-655) in patients with advanced NSCLC and other solid tumors harboring ALK rearrangement or activating ALK mutation (ALKOVE-1). ClinicalTrials.gov identifier: NCT05384626. Updated November 6, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT05384626
  5. Neladalkib (NVL-655) for TKI-naive patients with advanced ALK-positive NSCLC (ALKAZAR). ClinicalTrials.gov identifier: NCT06765109. Updated September 30, 2026. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT06765109

Related to this article